Do analysts prefer THAR or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, THAR or QNTM?

Tharimmune is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is THAR or QNTM more profitable?

Tharimmune's return on equity of -588.45% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Quantum Biopharma N/A -941.54% -224.41%

Do analysts recommend QNTM or CYPH?

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 29.95%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Cypherpunk Technologies is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, QNTM or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is QNTM or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Cypherpunk Technologies N/A -48.33% -42.21%

Does the media favor QNTM or CYPH?

In the previous week, Quantum Biopharma had 5 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Quantum Biopharma's score of 0.58 indicating that Cypherpunk Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer QNTM or ATRA?

Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 7.59%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor QNTM or ATRA?

In the previous week, Quantum Biopharma had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.84 beat Quantum Biopharma's score of 0.58 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACRV or QNTM?

Acrivon Therapeutics presently has a consensus price target of $11.67, indicating a potential upside of 645.47%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ACRV or QNTM?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is ACRV or QNTM more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Quantum Biopharma N/A -941.54% -224.41%

Does the media refer more to ACRV or QNTM?

In the previous week, Quantum Biopharma had 4 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for Acrivon Therapeutics. Quantum Biopharma's average media sentiment score of 0.58 beat Acrivon Therapeutics' score of 0.05 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CLNN or QNTM?

Clene currently has a consensus target price of $33.25, suggesting a potential upside of 533.94%. Given Clene's stronger consensus rating and higher possible upside, research analysts clearly believe Clene is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, CLNN or QNTM?

Clene is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 335.16 -$26.17M -$3.20 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is CLNN or QNTM more profitable?

Quantum Biopharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Quantum Biopharma N/A -941.54% -224.41%

Does the media favor CLNN or QNTM?

In the previous week, Quantum Biopharma had 5 more articles in the media than Clene. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Clene. Quantum Biopharma's average media sentiment score of 0.58 beat Clene's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quantum Biopharma (QNTM) Competitors

$2.81 -0.24 (-7.87%)

As of 03:23 PM Eastern

Compare

QNTM vs. THAR, CYPH, ATRA, ACRV, and CLNN

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Tharimmune (THAR), Cypherpunk Technologies (CYPH), Atara Biotherapeutics (ATRA), Acrivon Therapeutics (ACRV), and Clene (CLNN).

How does Quantum Biopharma compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Quantum Biopharma (NASDAQ:QNTM) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Quantum Biopharma had 6 more articles in the media than Tharimmune. MarketBeat recorded 6 mentions for Quantum Biopharma and 0 mentions for Tharimmune. Quantum Biopharma's average media sentiment score of 0.58 beat Tharimmune's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Quantum Biopharma	Positive

Tharimmune is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Tharimmune's return on equity of -588.45% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Quantum Biopharma	N/A	-941.54%	-224.41%

Summary

Quantum Biopharma beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Cypherpunk Technologies?

Quantum Biopharma (NASDAQ:QNTM) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, Quantum Biopharma had 5 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Quantum Biopharma's score of 0.58 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 29.95%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Cypherpunk Technologies is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Quantum Biopharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Cypherpunk Technologies' return on equity of -48.33% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Cypherpunk Technologies beats Quantum Biopharma on 9 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Atara Biotherapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Quantum Biopharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Atara Biotherapeutics has higher revenue and earnings than Quantum Biopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Atara Biotherapeutics	$23.14M	3.44	$32.69M	-$0.67	N/A

Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 7.59%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Quantum Biopharma had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.84 beat Quantum Biopharma's score of 0.58 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum Biopharma has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Summary

Atara Biotherapeutics beats Quantum Biopharma on 11 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Acrivon Therapeutics' return on equity of -64.43% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Quantum Biopharma	N/A	-941.54%	-224.41%

Acrivon Therapeutics presently has a consensus price target of $11.67, indicating a potential upside of 645.47%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quantum Biopharma had 4 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for Acrivon Therapeutics. Quantum Biopharma's average media sentiment score of 0.58 beat Acrivon Therapeutics' score of 0.05 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Acrivon Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

Acrivon Therapeutics beats Quantum Biopharma on 9 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Clene?

Clene (NASDAQ:CLNN) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Quantum Biopharma had 5 more articles in the media than Clene. MarketBeat recorded 6 mentions for Quantum Biopharma and 1 mentions for Clene. Quantum Biopharma's average media sentiment score of 0.58 beat Clene's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	335.16	-$26.17M	-$3.20	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Clene has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

23.3% of Clene shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Quantum Biopharma	N/A	-941.54%	-224.41%

Clene currently has a consensus target price of $33.25, suggesting a potential upside of 533.94%. Given Clene's stronger consensus rating and higher possible upside, research analysts clearly believe Clene is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Clene beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.92M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.34	7.36	279.98	25.51
Price / Sales	N/A	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.09	17.18	11.15	6.35
Net Income	-$26.17M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-6.63%	2.48%	2.51%	3.14%
1 Month Performance	-20.20%	-5.41%	-2.78%	-2.08%
1 Year Performance	-89.92%	51.14%	64.32%	21.27%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.6928 of 5 stars	$2.81 -7.9%	N/A	-87.1%	$17.97M	N/A	N/A	N/A	News Coverage Upcoming Earnings Analyst Upgrade
THAR Tharimmune	N/A	$2.05 -10.9%	N/A	+55.6%	$77.35M	N/A	N/A	2	Positive News Gap Up
CYPH Cypherpunk Technologies	2.2634 of 5 stars	$0.74 +3.1%	$0.90 +21.8%	+108.1%	$76.32M	N/A	N/A	40	News Coverage
ATRA Atara Biotherapeutics	1.4469 of 5 stars	$8.63 +4.1%	$9.50 +10.1%	-26.0%	$74.69M	$120.77M	N/A	330	News Coverage Positive News Upcoming Earnings
ACRV Acrivon Therapeutics	3.7178 of 5 stars	$1.75 +0.6%	$11.67 +566.7%	+23.8%	$74.47M	N/A	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. THAR, CYPH, ATRA, ACRV, and CLNN

How does Quantum Biopharma compare to Tharimmune?

Summary

How does Quantum Biopharma compare to Cypherpunk Technologies?

Summary

How does Quantum Biopharma compare to Atara Biotherapeutics?

Summary

How does Quantum Biopharma compare to Acrivon Therapeutics?

Summary

How does Quantum Biopharma compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. THAR, CYPH, ATRA, ACRV, and CLNN

How does Quantum Biopharma compare to Tharimmune?

Which has more risk and volatility, THAR or QNTM?

Do analysts prefer THAR or QNTM?

Do institutionals & insiders have more ownership in THAR or QNTM?

Does the media refer more to THAR or QNTM?

Which has higher earnings & valuation, THAR or QNTM?

Is THAR or QNTM more profitable?

Summary

How does Quantum Biopharma compare to Cypherpunk Technologies?

Does the media favor QNTM or CYPH?

Do institutionals & insiders have more ownership in QNTM or CYPH?

Do analysts recommend QNTM or CYPH?

Which has higher valuation and earnings, QNTM or CYPH?

Which has more volatility and risk, QNTM or CYPH?

Is QNTM or CYPH more profitable?

Summary

How does Quantum Biopharma compare to Atara Biotherapeutics?

Is QNTM or ATRA more profitable?

Which has higher earnings & valuation, QNTM or ATRA?

Do analysts prefer QNTM or ATRA?

Do institutionals & insiders hold more shares of QNTM or ATRA?

Does the media favor QNTM or ATRA?

Which has more volatility and risk, QNTM or ATRA?

Summary

How does Quantum Biopharma compare to Acrivon Therapeutics?

Is ACRV or QNTM more profitable?

Do analysts prefer ACRV or QNTM?

Does the media refer more to ACRV or QNTM?

Which has better earnings and valuation, ACRV or QNTM?

Do insiders and institutionals believe in ACRV or QNTM?

Which has more volatility & risk, ACRV or QNTM?

Summary

How does Quantum Biopharma compare to Clene?

Does the media favor CLNN or QNTM?

Which has higher valuation and earnings, CLNN or QNTM?

Which has more risk & volatility, CLNN or QNTM?

Do institutionals & insiders hold more shares of CLNN or QNTM?

Is CLNN or QNTM more profitable?

Do analysts recommend CLNN or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools